RxDoctor Payments Data

Jason Strefling, DO

Cardiovascular Disease · Lubbock, TXNPI 1720215296

Payments from drug & device makers

$32,713in general payments, 2019–2025

Across 505 payments — averaging $64.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$22K
  • Boston Scientific$2K
  • Novartis$2K
  • Abbott$2K
  • Medtronic$1K
  • Shockwave Medical, Inc$559
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$1,3954%
  • Speaking & faculty fees$18,95058%
  • Travel & lodging$1440%
  • Food & beverage$12,07337%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,713 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$269,810
Medicare patients
788
Services billed
2,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$380,895
XareltoRivaroxaban136$111,562
EntrestoSacubitril/Valsartan91$88,985
Repatha SureclickEvolocumab131$83,005
FarxigaDapagliflozin Propanediol80$62,954
MultaqDronedarone Hcl33$34,200
BrilintaTicagrelor39$28,327
Ranolazine ErRanolazine156$16,743
Praluent PenAlirocumab32$15,676
VascepaIcosapent Ethyl22$11,562
JardianceEmpagliflozin11$6,170
Metoprolol Succinate416$5,275
Rosuvastatin Calcium456$5,175
Atorvastatin Calcium530$4,223
Bumetanide128$3,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$396$380,895410 claims
Johnson & JohnsonXarelto$330$111,562136 claims
AstraZenecaFarxiga, Brilinta$21,724$91,281119 claims
NovartisEntresto$1,602$88,98591 claims
Sanofi-aventis U.S. LLCMultaq$201$34,20033 claims
Boehringer IngelheimJardiance$210$6,17011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →